A randomized multicenter trial comparing weekly docetaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] in the adjuvant treatment of women with high-risk breast cancer who are greater than 65 years old or are not candidates for anthracycline-based adjuvant therapy

Trial Profile

A randomized multicenter trial comparing weekly docetaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] in the adjuvant treatment of women with high-risk breast cancer who are greater than 65 years old or are not candidates for anthracycline-based adjuvant therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2008

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Fluorouracil; Methotrexate
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2008 Planned end date added (1 Dec 2009) as reported by ClinicalTrials.gov.
    • 27 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top